BioMarin Pharmaceutical

BMRNintermediary

BioMarin Pharmaceutical is a leader in rare-disease therapeutics with a portfolio of enzyme replacement therapies and the breakthrough growth drug Voxzogo for achondroplasia. Its Roctavian gene therapy for hemophilia A represents a one-time curative approach.

⇄ Compare

產品與營收

產品營收佔比

營收結構 ($2.8B)

靜態數據（加載即時財務…）

Enzyme Replacement Therapies (45%)

Voxzogo (30%)

Roctavian & Other (15%)

Royalties & Collaborations (10%)

業務部門構成與主要客戶

產品詳情

Voxzogo (vosoritide)30%

C-type natriuretic peptide analog for achondroplasia in children

Roctavian (AAV gene therapy)10%

Gene therapy for severe hemophilia A

Enzyme Replacement Therapies45%

Naglazyme, Vimizim, and Palynziq for lysosomal storage disorders and PKU

供應鏈關係

競爭對手

Regeneron Pharmaceuticals

Rare disease biologics

影響: Limited overlap in rare disease

Pfizer Inc.

Gene therapy platforms

影響: Competing in gene therapy

Novo Nordisk

Rare blood disorders

影響: Competing in hemophilia

宏觀與市場背景

제약 / 바이오行業新聞

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

近期催化劑

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

AI 分析

點擊「取得 AI 分析」以獲得 BioMarin Pharmaceutical 的 AI 供應鏈分析。

企業資訊

總部

San Rafael, California, USA

成立時間

1997

員工人數

4,200+

官網

biomarin.com

行業概況 — 제약 / 바이오

行業新聞